Breaking Out, Episode 4: 1726 nm laser you can book — denifanstat still a watch

Episodes 1–3 were prescriptions you pick up: Winlevi (Episode 1), Cabtreo (Episode 2), oral isotretinoin (Episode 3). This episode is for the person who heard “Accutane” and said no — pregnancy programme, labs, mood worries, dry everything — or who cannot take it. The 2026 path that already has a booking desk is a 1726 nm laser that heats oil (sebum) inside sebaceous glands more than the water around them.

That is a device story. The FDA cleared AviClear and Accure through 510(k) (substantially equivalent Class II lasers), not a drug NDA. Health Canada cleared AviClear (manufacturer announcement July 2022); Canadian clinics already run the series. The oral pill people are watching — denifanstat — is still a watch. China’s Phase 3 finished (NCT06192264 COMPLETED). China’s NMPA accepted an NDA in December 2025 — that is a regulatory clock in China, not a bottle in North America. Sagimet’s US AURORA Phase 3 is not RECRUITING on ClinicalTrials.gov A cleared laser is not an open pill trial.

Where this is taking place

Clinic path (now): dermatology / medical aesthetic practices that own an AviClear or Accure system. United States (both devices FDA-cleared). Canada (AviClear clinics documented; Accure HC licence not found). UK and Australia: AviClear offered in private clinics (TGA-cleared per manufacturer/clinic; ARTG ID not confirmed on this page). Accure also has CE Mark history in Europe.

Trial path (not yet for denifanstat US): Ascletis China Phase 3 NCT06192264 and OLE NCT06248008 are COMPLETED. China NMPA NDA accepted (Dec 2025) — watch. Sagimet AURORA US Phase 3: company says screening toward Q4 2026 — no RECRUITING NCT to hand a site coordinator today.

This is not a Canadian SAP drug story. AviClear is a cleared energy device used in clinic. Denifanstat is not a marketed pill in Canada/US.

Approval matrix (1726 nm acne lasers — device clearance)

Device clearance, not a drug approval: this episode’s path is Health Canada/FDA Cleared (medical device) for AviClear (HC + FDA), with Accure as an FDA-cleared peer — a cleared device, not an “FDA-approved pill.” In Canada, the documented HC path is AviClear, not Accure.

Access by country

• United States: Ask a dermatologist or acne-focused clinic whether they offer AviClear and/or Accure. Both are FDA 510(k)–cleared for mild to severe inflammatory acne. Typical series: AviClear 3× ~30 min; Accure 4× ~monthly (confirm with that office). Expect cash-pay package pricing unless your insurer has a written policy (coverage unknown — do not assume). Find providers via manufacturer locators (aviclear.com, accureacne.com) and verify the device name on the consent form.
• Canada: Documented path is AviClear in private / derm clinics. Health Canada clearance announced 2022; licence number unknown. Accure HC licence not found. Pricing on public clinic menus is cash-pay multi-session packages — confirm the written quote. Provincial public coverage: unknown. SAP is the wrong door for a cleared device already in Canadian clinics.
• United Kingdom: Private AviClear clinics publish package prices. Clinic pages checked state not NHS. Ask a dermatologist who lists AviClear.
• Australia: TGA-cleared per manufacturer; private clinics offer series. PBS / public funding unknown. Cash-pay.
• EU / other: Accure CE history; AviClear limited EU rollout 2024. Availability is clinic-by-clinic. Cross-border device import is not a patient plan.
• If no local 1726 nm clinic: do not buy a “home laser.” Ask about labelled topicals (Episodes 1–2) or whether isotretinoin (Episode 3) is still off the table for medical reasons.

Denifanstat (watch only — not Access Level)

---

What it actually is

1726 nm is a mid-infrared wavelength where sebum absorbs laser energy preferentially versus water (selective photothermolysis of sebaceous glands). The gland is injured in a controlled way; oil production drops; inflammatory acne improves over months — including after the last session in published follow-up.

AviClear (Cutera): diode 1726 nm; contact sapphire cooling (AviCool); treats to a fluence endpoint; ~30 minutes; usually three sessions.

Accure (Accure Acne): fiber 1726 nm; forced-air cooling; real-time temperature monitoring; treats to a peak epidermal temperature endpoint; often four sessions; derm-office focus per company.

It is not:

• isotretinoin, Winlevi, or Cabtreo
• a drug “approval” (NDA/NOC for a pill)
• a guarantee of clear skin
• Accure-as-HC-cleared in Canada (not found)
• denifanstat in your pharmacy
• an NHS / provincial insured benefit on evidence reviewed here

Contrast with Episodes 1–3

---

What the evidence showed (plain numbers)

AviClear FDA IDE study (K213461 summary): n=104, ages 16–40, mild–severe facial inflammatory acne, three treatments. At 12 weeks after last treatment, 77.9% (ITT) met ≥50% fewer inflammatory lesions. Clear/almost clear with ≥2 IGA grade improvement: about 31% ITT at that visit. Published extensions (Goldberg; Alexiades JAAD 2023) report continued improvement and high rates of ≥1-grade IGA improvement at later follow-up — useful, not a second independent registrational drug NDA.

Accure: company and conference data (Tanghetti and others; Skin Therapy Letter 2024 review) describe large lesion reductions after four monthly treatments; much of the long-term Accure dataset was still preliminary/unpublished at that review. No head-to-head vs AviClear.

Limitations: studies emphasize inflammatory lesions; comedonal-only disease is less characterized. Truncal (back) outcomes are thinner in early literature. Cash cost and operator skill matter. “All skin types” safety claims rest on low pigment absorption at 1726 nm plus cooling — still demand an experienced operator and sun care.

---

Safety a household should actually watch

Expected and usually short-lived: redness, swelling, temporary acne flare (“purging”), dryness. Discomfort during treatment is real (AviClear IDE average pain ~5/10 without stopping sessions). Accure Standard Mode may use injectable anesthetic; Boost Mode topical — ask which protocol you are signing up for.

Rare but ask about: prolonged redness, crusting, pigment change, scarring (not seen in the AviClear IDE summary through 12 weeks; still a laser). Photosensitivity after treatment: sunscreen and sun avoidance as the clinic instructs.

Not a systemic retinoid programme: no iPLEDGE / PPP monthly labs for the laser itself. That does not make it risk-free. Pregnancy: discuss with the clinician before elective laser; follow that clinic’s policy.

Under-16: AviClear IDE enrolled from 16; adolescent commercial use appears in clinic advertising — confirm age policy and guardian consent locally. Accure ages: ask the derm office.

---

Eligibility (plain language)

More likely a fit if:

• You have mild to severe inflammatory acne (face; ask about neck/back).
• You want a non-pill option, or isotretinoin is medically / personally off the table.
• You can complete a 3- or 4-session series and pay cash/private (or have written insurance approval).
• You accept downtime measured in days of redness, not months of systemic side effects.

Ask hard before booking if:

• Active infection, recent isotretinoin (clinic washout rules vary), keloid tendency, unrealistic “one session clears forever” expectation.
• You came looking for denifanstat — that door is not open on ClinicalTrials.gov yet.

---

Access: what you can actually do

1. This episode’s Access Level is the laser — device clearance, clinic booking

Book a consult at a practice that names AviClear or Accure on the consent. In Canada, verify AviClear (Accure HC not found). Bring prior acne history: topicals tried, antibiotics, hormones, isotretinoin exposure, pregnancy status.

2. Who performs it

Trained clinic staff under a physician’s medical director model, or the dermatologist personally — rules differ by province/state. Ask: who fires the laser, who is on site, what happens if you blister. Accure markets to board-certified dermatologist offices.

3. Doctor / consult script

I am looking at a 1726 nm sebaceous-gland laser because I cannot or will not take isotretinoin. AviClear is FDA 510(k)–cleared (K213461, March 2022; long-term K230660, June 2023) for mild to severe inflammatory acne, and Cutera announced Health Canada clearance in July 2022 — Canadian clinics already offer it. Accure is FDA-cleared (K222109 / long-term K242035) but I understand a Canadian Accure licence was not found. Can you confirm which device you use, how many sessions, who operates it, total cash price for the full series, financing, sun-care rules, and whether my acne type (inflammatory vs mostly comedones; face vs back) matches the cleared indication? I am not asking for denifanstat — Sagimet’s US AURORA Phase 3 is not RECRUITING on ClinicalTrials.gov yet, and China’s NMPA NDA acceptance is not a North American prescription.

Ask:

1. Device name on the consent (AviClear vs Accure vs something else)?
2. Full series price before add-ons?
3. Sessions and spacing?
4. Who operates; physician on site?
5. Photos / IGA plan so you can judge response at 3 and 12 months?
6. Interaction with any topicals you still use?
7. Denifanstat: only if an NCT appears as RECRUITING — otherwise watch.

4. Money

Expect cash-pay / private unless you have a written insurer approval (coverage unknown). Compare a full series (AviClear typically 3; Accure typically 4), not a single-session teaser. Public coverage: unknown. Financing plans are private debt — read the APR. No Medcelerator dollar amount is a quote.

5. Denifanstat watch list (not a booking)

• Check ClinicalTrials.gov for denifanstat or ASC40 + acne + RECRUITING.
• Completed China: NCT06192264, NCT06248008.
• China NMPA NDA accepted Dec 2025: watch, not access.
• Do not confuse with Sagimet TVB-3567 Phase 1 NCT06989840.
• No compassionate-use programme found for denifanstat in Canada/US.

6. If the answer is “not a candidate”

Return to labelled topicals (Episodes 1–2), dual combos your country authorises, or revisit isotretinoin (Episode 3) with a derm who runs the safety programme. A 1726 nm series is one tool — not the only acne path in 2026.

---

Bottom line

1726 nm lasers (AviClear, Accure) are a real, cleared-device option for mild to severe inflammatory acne when pills are off the table. AviClear has FDA 510(k) clearance and a documented Canadian clinic path after Health Canada clearance (licence number unknown). Accure has FDA clearance and CE history; Canadian Accure licence not found. Expect three or four cash-pay sessions, temporary redness/flare, and months of continued clearing — not a miracle in a weekend.

Denifanstat stays in the “next” column until ClinicalTrials.gov shows a RECRUITING US Phase 3 NCT. China’s Phase 3s are done; NMPA NDA acceptance is a watch; AURORA is planned, not open. This episode’s Access Level is the laser, precisely as device clearance — not a denifanstat approval headline, and not a drug “Health Canada/FDA Approved” story.

---

Who (from sources only)

Names and teams below are as they appear on primary sources. Clinic directories: use manufacturer locators.

---

Primary sources

1. FDA 510(k) K213461 — AviClear Laser System, decision 24 Mar 2022. Indications: mild to severe inflammatory acne vulgaris. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K213461 (openFDA confirmation 2026-09-04: Substantially Equivalent).
2. FDA 510(k) K230660 — AviClear, decision 6 Jun 2023 (long-term treatment clearance listing). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K230660
3. FDA 510(k) K222109 — Accure Laser System, decision 17 Nov 2022. Mild to severe inflammatory acne vulgaris. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K222109
4. FDA 510(k) K242035 — Accure Laser System, decision 11 Oct 2024. Long-term treatment mild to severe inflammatory acne vulgaris. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K242035
5. Cutera. Health Canada Clears Cutera’s AviClear (BusinessWire, 13 Jul 2022). Mild/moderate/severe acne and acne scars. https://www.businesswire.com/news/home/20220713005256/en/Health-Canada-Clears-Cuteras-AviClear
6. Cutera. FDA Clears AviClear as a Long-Term Treatment (BusinessWire, 15 Jun 2023). https://www.businesswire.com/news/home/20230615985076/en/FDA-Clears-AviClear-as-a-Long-Term-Treatment-for-Mild-to-Severe-Acne
7. Accure Acne, Inc. FDA clearance PR (22 Nov 2022). https://www.prnewswire.com/news-releases/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris-301684625.html
8. Bittar J, Hooper P, Dover JS. 1726 nm Lasers for the Treatment of Acne Vulgaris. Skin Therapy Letter. https://www.skintherapyletter.com/acne/1726-nm-lasers/
9. Goldberg D, et al. Selective photothermolysis with a novel 1726 nm laser beam. J Cosmet Dermatol. 2023;22(2):486-496.
10. Alexiades M, et al. Novel 1726 nm laser demonstrates durable therapeutic outcomes… J Am Acad Dermatol. 2023;89(4):703-710.
11. ClinicalTrials.gov NCT06192264 — ASC40 (denifanstat) Phase 3 China — COMPLETED. https://clinicaltrials.gov/study/NCT06192264
12. ClinicalTrials.gov NCT06248008 — ASC40 OLE China — COMPLETED. https://clinicaltrials.gov/study/NCT06248008
13. Ascletis / Sagimet. China NMPA NDA acceptance for denifanstat acne (10 Dec 2025) — watch only. https://sagimetbiosciences.gcs-web.com/news-releases/news-release-details/sagimets-license-partner-ascletis-announced-acceptance-new-drug/
14. Sagimet Biosciences. FDA Study May Proceed / IND for Phase 3 acne (13 Aug 2026). https://www.globenewswire.com/news-release/2026/08/13/3344344/0/en/sagimet-biosciences-receives-fda-study-may-proceed-letter-and-ind-clearance-for-phase-3-trial-in-acne-in-adolescent-and-adult-patients.html
15. Sagimet Biosciences. AURORA advances toward enrollment Q4 2026 (25 Aug 2026). https://www.biospace.com/press-releases/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patient-enrollment-in-q4-2026
16. Manufacturer patient pages: https://aviclear.com/en-us/why-aviclear/ ; https://accureacne.com/the-accure-acne-laser-system/
17. Cutera AU product page (TGA-cleared claim). https://cutera.com/au-en/products/aviclear/
18. ClinicalTrials.gov API query denifanstat+acne / Sagimet acne — versionHolder 2026-09-04: no RECRUITING AURORA NCT; NCT06989840 is TVB-3567 Phase 1 (different asset).

---

Not a substitute for a clinician who treats acne.